Table 2.
Expression and inhibitory potency of cystatins against proteases from different aged nodules
| Cystatin | Expression | Cat-L inhibition | Cat-B inhibition |
|---|---|---|---|
| Active | |||
| 4 weeks | |||
| Glyma05g28250 | + (22.65) | + (36.1%) | + (32.8%) |
| Glyma13g04250 | + (97.58) | + (26.4%) | + (27.6%) |
| Glyma14g04250 | (−) (2.14) | (−) | (−) |
| Glyma15g36180 | + (26.34) | ++ (49.9%) | ++ (48.7%) |
| Glyma20g08800 | + (85.83) | (−) | (−) |
| 14 weeks | |||
| Glyma05g28250 | + (39.78) | + (30.6%) | (−) |
| Glyma13g04250 | + (63.86) | + (29.7%) | (+) (24.9%) |
| Glyma14g04250 | (+) (12.38) | (+) (21.9%) | (−) |
| Glyma15g36180 | + (55.64) | (−) | (−) |
| Glyma20g08800 | + (56.25) | (−) | (−) |
| Non-active | |||
| 4 weeks | |||
| Glyma04g10360 | (−) (0) | + (38.6%) | + (35.3%) |
| Glyma07g39590 | (−) (2.09) | + (47.5%) | + (42.3%) |
| Glyma08g11210 | (−) (0) | + (43.6%) | + (42.1%) |
| Glyma18g12240 | (−) (0.28) | ++ (54.0%) | + (36.6%) |
| Glyma13g27980 | (−) (0) | + (33.2%) | + (42.0%) |
| 14 weeks | |||
| Glyma04g10360 | (−) (0) | + (39.0%) | + (28.6%) |
| Glyma07g39590 | (−) (1.23) | ++ (51.3%) | + (34.0%) |
| Glyma08g11210 | (−) (0) | + (33.5%) | (−) |
| Glyma18g12240 | (−) (0.58) | ++ (51.5%) | (+) (22.4%) |
| Glyma13g27980 | (−) (0) | (−) | (−) |
++ strong, + medium. (+) low and (−) no cystatin expression/or activity (tested up to 1 mM). Expression indicated as measured FPKM abundances and activity indicated as% inhibition.